Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777775 · ClinicalTrials.gov registry record
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
A clinical trial of Neurofibromatosis Type 1 and Plexiform Neurofibromas, sponsored by Corewell Health West.
- Completed
- Registry status
- 71
- Enrollment target
- 1
- Study location
NCT02777775 is a study of Neurofibromatosis Type 1 and Plexiform Neurofibromas that has completed, run by Corewell Health West. The registered enrollment target is 71 participants, below the 156-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02777775, a study of Neurofibromatosis Type 1 and Plexiform Neurofibromas, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research study is intended to use specimens (such as tissue) and medical information in the Laboratory of Musculoskeletal Oncology at the Van Andel Research Institute for laboratory research in Grand Rapids, Michigan. Small tissue samples of cutaneous neurofibromas will be collected as part of this research. The samples will help researchers learn more about cutaneous neurofibroma and help them better understand NF1. There are many different types of studies, both now and in the future, that can be done using the specimens the investigators receive. These include using the specimens and information to look for new ways to diagnose and treat Neurofibromatosis Type 1 (NF1). The specimens may be used to study how genes affect health and disease, or how genes affect the way a disease or condition responds to treatment. Some of these studies may lead to new products, such as treatments or tests for diseases. Through this study, the investigators hope to find better ways to understand and treat NF1 in the future.
Conditions Studied
Interventions
- PROCEDURE Skin Biopsy
Study Locations (1)
Michigan
- Spectrum Health Hospital Group - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2016-05 |
| Est. Completion | 2025-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02777775
The ClinicalTrials.gov registry entry for NCT02777775 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 17 other Neurofibromatosis Type 1 trials with a reported enrollment target (54% lower). The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neurofibromatosis Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Skin Biopsy is the first listed.
NCT02777775 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02777775 about?
NCT02777775 is a clinical study titled "Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.". The purpose of the research study is intended to use specimens (such as tissue) and medical information in the Laboratory of Musculoskeletal Oncology at the Van Andel Research Institute for laboratory research in Grand Rapids, Michigan. Small tissue samples of cutaneous neurofibromas will be collect...
What is the current status of trial NCT02777775?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2016-05. Estimated completion is 2025-06.
What conditions does trial NCT02777775 study?
This clinical trial studies the following conditions: Neurofibromatosis Type 1, Plexiform Neurofibromas, Cutaneous Neurofibromas.
What interventions are being tested in trial NCT02777775?
The interventions under investigation include: Skin Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02777775?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02777775 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
RECRUITING · NA
-
Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study
RECRUITING
-
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
RECRUITING · NA
-
Neurofibromatosis Type 1 Tumor Early Detection Study
RECRUITING
-
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
RECRUITING · Phase 2
-
Natural History Study of Patients With Neurofibromatosis Type I
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.